Viewing Study NCT06817720


Ignite Creation Date: 2025-12-25 @ 4:12 AM
Ignite Modification Date: 2026-02-25 @ 8:56 PM
Study NCT ID: NCT06817720
Status: RECRUITING
Last Update Posted: 2025-10-15
First Post: 2025-02-04
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module